Business Wire

Primex Pharmaceuticals Appoints Jostein Davidsen and Angelo Colombo as Board Members

Del

Jostein Davidsen brings over 30 years of experience from the international pharmaceutical industry, most recently serving as CEO of Acino Pharmaceuticals in Switzerland.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170503005582/en/

Primex Pharmaceuticals appoints Jostein Davidsen and Angelo Colombo (in picture) as board members. ( ...

Primex Pharmaceuticals appoints Jostein Davidsen and Angelo Colombo (in picture) as board members. (Photo: Business Wire)

Mr. Davidsen was the founder of Nycomed Russia-CIS which he built up to be one of the leading pharmaceutical companies in the region, until being sold to Takeda Pharmaceuticals in 2011. Davidsen then became Corporate Officer and Head of the Emerging Markets at Takeda in Zurich. He was named the world's second most influential pharma-industry leader in Emerging Markets by pharma news service Scrip.

Angelo Colombo has 25 years of experience from the pharmaceutical sector. Recently, he was Managing Director at Corden Pharma Spa with extensive experience in the manufacture of pharmaceuticals, especially injectables.

Previously, Mr. Colombo was the Nerviano site leader for Pfizer, one of the largest pharmaceutical R&D centers for oncology in Europe. He was also General Manager at Pierrel, a leading dental anaesthetic manufacturer. In these roles, Colombo obtained FDA and EMEA approvals at all sites, built a new injectable department with the highest technology standards and developed new formulations.

Panu Paappanen, Chairman of the Board, commented: "With these appointments the board gains senior pharma executives to strengthen the strategic expertise in growing our global pharmaceutical business.”

Kari Sarvanto, CEO and Co-Founder of Primex, added: “I am delighted that we can attract experienced pharmaceutical professionals to our board, at a time when Primex is progressing to a new and exciting stage of strong and sustainable growth.”

About Primex Pharmaceuticals:

Primex Pharmaceuticals aims to become the leading global innovative anaesthesia company, and to expand in paediatric and orphan pharmaceuticals.

A portfolio of strong, trusted anaesthesia products from propofol-based products acquired from Bayer to a novel oral solution for paediatric procedural sedation, is helping patients undergo a wide range of medical procedures. Primex Pharmaceuticals continues to identify and acquire new medications that complete the ‘Triad of Anaesthesia’.

Primex Pharmaceuticals' global partner network operates in over 40 countries. The company is headquartered in Switzerland; all Primex products are manufactured in Europe. Primex Pharmaceuticals has proven underlying business operations and historically strong revenue growth.

www.primexpharma.com

Contact information

Primex Pharmaceuticals
Mr. Kari Sarvanto, Group CEO
Mobile: +41 796 162 694
Email: kari.sarvanto@primexintl.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Eos Biosciences Announces Issuance of Additional U.S. Patent For Targeted Breast Cancer Therapy17.10.2017 11:00Pressemelding

Eos Biosciences, Inc., a bio-targeted nanomedicines company developing a novel nanobiologic particle drug delivery platform technology (Eosomes), and a proprietary oncology-specific product pipeline, announced that the U.S. Patent and Trademark Office has now issued Eos Biosciences a second patent, U.S. Patent No. 9,789,201, for Eos-001, the company’s HER3-targeted Eosome with doxorubicin payload. Omar Haffar, Ph.D., Founder, President and Chief Executive Officer, commented, “This is a very exciting time for Eos Biosciences. In addition to expanding and solidifying our patent portfolio, we are making very significant progress on the pre-clinical development and scale-up manufacturing of our products.” Dr. Haffar continued, “We are also implementing a strategic expansion of our product pipeline into immuno-oncology, and the application of Eosomes to other high impact di

First Eagle Investment Management Agrees to Acquire NewStar Financial17.10.2017 11:00Pressemelding

First Eagle Investment Management (“First Eagle”) and NewStar Financial Inc. (Nasdaq:NEWS) ("NewStar”) announced today that they have entered into a definitive agreement for First Eagle to acquire NewStar, an established lender and investment manager specializing in direct lending to middle-market companies and management of broadly syndicated loans. NewStar stockholders are expected to receive total consideration estimated at $12.32 to $12.44 per share, which represents a premium of 10.4% to 11.5% over NewStar's 3-month volume weighted average price of $11.16 as of October 16, 2017, the last trading day before the transaction announcement. The contingent value rights entitle the holders to certain tax refunds generated by the transaction, the amount of which will vary depending upon, among other things, whether the transaction closes in 2017 or 2018. This press release features multimedia.

1 Million MOTION CODE™ Online Transactions With Société Générale17.10.2017 10:07Pressemelding

IDEMIA, the global leader in trusted identities for an increasingly digital world, today announced the milestone of 1 million MOTION CODE TM online transactions with Société Générale. Société Générale was one of the first banks worldwide to launch MOTION CODE™, the next-generation card integrating a dynamic security code by IDEMIA (formerly known as OT-Morpho). This solution consists in replacing the 3 digits of the cryptogram printed on the back of the card with a small screen displaying a new “dynamic” code every hour. Thus, in case of piracy of the bank card’s data, the 3 digits of the cryptogram quickly become obsolete, preventing fraudsters from reusing data, especially on e-commerce sites. After successful testing among more than 500 people in 2016, Société Générale started offering MOTION CODE™ to all their French customers early 2017. In les

Mobile Ticket Option Launches for Tampa Bay CityPASS17.10.2017 09:00Pressemelding

City Pass, Inc., the company that specializes in packaging discounted admission to the most iconic attractions in 12 North American destinations, recently launched a mobile ticket option for its Tampa Bay CityPASS® program. Since 1997, CityPASS products have been designed to make travel easier and less expensive. And while the Tampa Bay CityPASS program will continue to excel at the latter—saving visitors 51 percent off combined admission to the included attractions—the new mobile ticket option dramatically enhances the convenience factor. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171017005538/en/ Busch Gardens Tampa Bay (Photo: SeaWorld Parks & Entertainment, Inc.) “We’re always looking for ways to improve the customer experience and make travel more convenient,” said CityPASS President a

Sigma Systems Appoints Vladimir Mitrasinovic as Senior Vice-President of Sales and Managing Director for EMEA and APAC17.10.2017 08:00Pressemelding

Sigma Systems, the leader in catalog-driven software, has appointed Vladimir Mitrasinovic as Senior Vice-President of Sales and Managing Director for EMEA and APAC. Mr. Mitrasinovic was previously Head of the Cloud and Software as a Service business unit for Cerillion Technologies, and served as Executive Vice-President of Global Channels and Alliances at Acision (XURA). As Senior Vice President of Sales and Managing Director of EMEA and APAC, Vladimir will oversee all sales and business development efforts within the regions. “We are delighted to welcome Vladimir to the Sigma team,” said Simon Muderack, Sigma’s Executive Vice President and Chief Commercial Officer. “Vladimir’s background in high-growth corporate development in the technology sector and experience in sales and business expansion will be an excellent asset to Sigma as we continue to expand across EMEA and

MagicStay, The Start-up of Short-Term Rental for Business, Affirms Its Ambitions at the Web Summit 201717.10.2017 08:00Pressemelding

The French start-up MagicStay.com launched 3 years ago, now offers more than 130,000 apartments in 110 countries on its specialized platform for business travelers. As the only 100% B2B platform, MagicStay has developed many services adapted to the requirements of businesses, especially in terms of security and integration into their tools, which will be presented at the Web Summit in Lisbon from 6 to 9 November. For three years now, the start-up has been developing an exclusive technology that makes it possible to provide a global supply of short-term rentals in immediate reservations. These professionally managed accommodations meet corporate requirements: security, legislation compliance, and integration into booking tools used by corporate companies. "The Business Travel Market is very complex in terms of technology and actors, and is highly

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom